

Development of ^{211}At -labeled antibody for targeted alpha therapy

Y. Kanayama,^{*1} K. Sakamoto,^{*2} E. Ebisui,^{*3} Y. Wang,^{*4} T. Yokokita,^{*4} Y. Komori,^{*4} D. Mori,^{*4} H. Haba,^{*4} and Y. Watanabe^{*1}

Radiotherapeutic agents labeled with various α -emitting nuclides have been developed for targeted alpha therapy. ^{211}At has a simple decay scheme and can avoid the risk of side effects caused by daughter nuclides; it is thus considered a useful α -emitter for this therapy. Given the requirements for ^{211}At -labeled pharmaceuticals in the future, RIKEN Nishina Center for Accelerator-Based Science aims to increase the ^{211}At production scale a global maximum; this prompted us to develop ^{211}At -labeled drugs and labeling methods.

For the attachment of ^{211}At , organotin compounds are the most widely used precursor owing to the weakness of the carbon-tin bond, which enables the use of a tin group as a leaving group.¹⁾ In this study, we used an organotin compound, *N*-succinimidyl-3-(trimethylstannyl)benzoate (m-MeATE), for ^{211}At labeling. According to the direct astatination procedure reported by Lindegren *et al.*,²⁾ m-MeATE was first conjugated with a monoclonal IgG. Then, m-MeATE and IgG were mixed at a molar ratio of 20:1 and incubated for 30 min at 25°C in a pH-8.5 NaCO₃ buffer. The attachment of ^{211}At was carried out by a modified protocol of the method of Li *et al.*³⁾ An oxidizing agent *N*-chlorosuccinimide (NCS) (0.2 mg/ml) was added to the ^{211}At solution in 1% acetic acid MeOH. Then an IgG/m-MeATE conjugate in a 0.2 M sodium acetate buffer was mixed with the activated ^{211}At solution, with the final MeOH and NCS concentrations being 11% and 3.6 $\mu\text{g}/\text{ml}$, respectively. The incubation was performed for 3 min. *N*-iodosuccinimide (0.2 mg/ml) was then added at a final concentration of 5.4 $\mu\text{g}/\text{ml}$, and the reaction mixture was incubated for another 1 min. For purification, an Amicon Ultra 50 kDa column (Merck) was used in ultrafiltration.

Finally, 5.6 MBq of ^{211}At -labeled IgG was obtained using 40 MBq of ^{211}At -MeOH (shown in Table 1). In this experiment, we did not reach the labeling yield that Li *et al.* reported previously ($40.2 \pm 6.9\%$).³⁾ Further, we examined the use of a PD Spintrap G-25 gel filtration column for purification, only to reduce the yield.

To demonstrate the usefulness of the ^{211}At -labeled IgG, we performed a biodistribution study using the mice with xenografted tumors specific to IgG. Three and 24 h after the ^{211}At -labeled IgG i.v. injections, the mice were dissected to measure tissue radioactivity. As a control group, free ^{211}At was also administered. The results are shown in Fig. 1. Unexpectedly, the distribution of ^{211}At -labeled IgG was almost the same as that of




Fig. 1. Biodistribution of free ^{211}At and ^{211}At -labeled antibody 3 and 24 h after i.v. injection in the tumor-bearing mice.

Table 1. Labeling results of ^{211}At -labeled IgG purified by ultrafiltration or gel filtration.

Purification method	Radioactivity yield [%]	Protein yield [%]	Specific activity [kBq/ μg]
Ultrafiltration	13.9	75.0	12.9
Gel filtration	5.0	69.5	14.9

Table 2. Labeling results of ^{211}At -labeled IgG or IgG/m-MeATE purified by reduced nonspecific binding gel.

Precursor	Radioactivity yield [%]	Protein yield [%]	Specific Activity [kBq/ μg]
IgG/m-MeATE	43.9	85.6	31.6
Intact IgG	12.9	79.3	12.5

free ^{211}At . The high accumulation rates in the stomach and thyroid indicated the physiological accumulation of ^{211}At detached from IgG.

From these results, we speculated that the increased hydrophobicity by astatination may have caused the nonspecific binding of ^{211}At -labeled IgG to column filters or gels in the purification step, resulting in a low radioactivity yield despite a high protein yield. To overcome this problem, we used a specialized gel to alleviate nonspecific binding. As shown in Table 2, the radioactivity yields were significantly improved.

In the next step, we will examine a labeling method using decaborane, which is expected to have a higher stability in bonding with ^{211}At in the body.

References

- 1) F. Guerard *et al.*, *Cancer Biother. Radiopharm.* **28**, 1 (2013).
- 2) S. Lindegren *et al.*, *J. Nucl. Med.* **49**, 1537 (2008).
- 3) H. K. Li *et al.*, *Cancer Sci.* **108**, 1648 (2017).

^{*1} Laboratory for Pathophysiological and Health Science, RIKEN

^{*2} Laboratory for Nonnatural Amino Acid Technology, RIKEN

^{*3} Liver Cancer Prevention Research Unit, RIKEN

^{*4} RIKEN Nishina Center